These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 31123470)

  • 1. Evaluation of Immune Response against Leishmaniasis in BALB/c Mice Immunized with Cationic DOTAP/DOPE/CHOL Liposomes Containing Soluble
    Hojatizade M; Badiee A; Khamesipour A; Jaafari MR
    Iran J Parasitol; 2019; 14(1):68-77. PubMed ID: 31123470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of protection against leishmaniasis in susceptible BALB/c mice using simple DOTAP cationic nanoliposomes containing soluble Leishmania antigen (SLA).
    Firouzmand H; Badiee A; Khamesipour A; Heravi Shargh V; Alavizadeh SH; Abbasi A; Jaafari MR
    Acta Trop; 2013 Dec; 128(3):528-35. PubMed ID: 23916506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cationic liposomes containing soluble Leishmania antigens (SLA) plus CpG ODNs induce protection against murine model of leishmaniasis.
    Heravi Shargh V; Jaafari MR; Khamesipour A; Jalali SA; Firouzmand H; Abbasi A; Badiee A
    Parasitol Res; 2012 Jul; 111(1):105-14. PubMed ID: 22223037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PEGylation of cationic liposomes encapsulating soluble Leishmania antigens reduces the adjuvant efficacy of liposomes in murine model.
    Naseri H; Eskandari F; Jaafari MR; Khamesipour A; Abbasi A; Badiee A
    Parasite Immunol; 2017 Nov; 39(11):. PubMed ID: 28921566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and protection effects of cationic liposome containing imiquimod adjuvant on leishmaniasis in BALB/c mice.
    Mehravaran A; Rezaei Nasab M; Mirahmadi H; Sharifi I; Alijani E; Nikpoor AR; Akhtari J; Hojatizade M
    Iran J Basic Med Sci; 2019 Aug; 22(8):922-931. PubMed ID: 31579449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liposomal SLA co-incorporated with PO CpG ODNs or PS CpG ODNs induce the same protection against the murine model of leishmaniasis.
    Shargh VH; Jaafari MR; Khamesipour A; Jaafari I; Jalali SA; Abbasi A; Badiee A
    Vaccine; 2012 Jun; 30(26):3957-64. PubMed ID: 22465747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of MPL and imiquimod adjuvants in enhancement of immune response and protection in BALB/c mice immunized with soluble Leishmania antigen (SLA) encapsulated in nanoliposome.
    Emami T; Rezayat SM; Khamesipour A; Madani R; Habibi G; Hojatizade M; Jaafari MR
    Artif Cells Nanomed Biotechnol; 2018; 46(sup2):324-333. PubMed ID: 29607698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cationic Immune Stimulating Complexes Containing Soluble Leishmania Antigens: Preparation, Characterization and in Vivo Immune Response Evaluation.
    Mehravaran A; Jaafari MR; Jalali SA; Khamesipour A; Tafaghodi M; Hojatizade M; Abbasi A; Badiee A
    Iran J Immunol; 2015 Dec; 12(4):274-87. PubMed ID: 26714419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cationic liposomes formulated with a novel whole Leishmania lysate (WLL) as a vaccine for leishmaniasis in murine model.
    Jafari I; Heravi Shargh V; Shahryari M; Abbasi A; Jaafari MR; Khamesipour A; Badiee A
    Immunobiology; 2018; 223(6-7):493-500. PubMed ID: 29317110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sphingomyelin Liposomes Containing Soluble Leishmania major antigens Induced Strong Th2 Immune Response in BALB/c Mice.
    Chavoshian O; Biari N; Badiee A; Khamesipour A; Abbasi A; Saberi Z; Jalali SA; Jaafari MR
    Iran J Basic Med Sci; 2013 Sep; 16(9):965-72. PubMed ID: 24171074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protection induced by Leishmania Major antigens and the imiquimod adjuvant encapsulated on liposomes in experimental cutaneous leishmaniasis.
    Mehravaran A; Nasab MR; Mirahmadi H; Sharifi I; Alijani E; Nikpoor AR; Akhtari J
    Infect Genet Evol; 2019 Jun; 70():27-35. PubMed ID: 30738195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of liposome charge on immune response generated in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63).
    Badiee A; Jaafari MR; Khamesipour A; Samiei A; Soroush D; Kheiri MT; Barkhordari F; McMaster WR; Mahboudi F
    Exp Parasitol; 2009 Apr; 121(4):362-9. PubMed ID: 19211022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increasing Cellular Immune Response in Liposomal Formulations of DOTAP Encapsulated by Fusion Protein Hspx, PPE44, And Esxv, as a Potential Tuberculosis Vaccine Candidate.
    Mansury D; Ghazvini K; Amel Jamehdar S; Badiee A; Tafaghodi M; Nikpoor AR; Amini Y; Jaafari MR
    Rep Biochem Mol Biol; 2019 Jan; 7(2):156-166. PubMed ID: 30805395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. siRNA delivery to lung-metastasized tumor by systemic injection with cationic liposomes.
    Hattori Y; Nakamura A; Arai S; Kawano K; Maitani Y; Yonemochi E
    J Liposome Res; 2015; 25(4):279-86. PubMed ID: 25543847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of in vivo Adjuvanticity of Liposomal PO CpG ODN with Liposomal PS CpG ODN: Soluble Leishmania Antigens as a Model.
    Golali E; Jaafari MR; Khamesipour A; Abbasi A; Saberi Z; Badiee A
    Iran J Basic Med Sci; 2012 Sep; 15(5):1032-45. PubMed ID: 23493437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Electrostatic parameters of cationic liposomes commonly used for gene delivery as determined by 4-heptadecyl-7-hydroxycoumarin.
    Zuidam NJ; Barenholz Y
    Biochim Biophys Acta; 1997 Oct; 1329(2):211-22. PubMed ID: 9371413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chitosan Nanoparticles Loaded with Whole and Soluble Leishmania Antigens, and Evaluation of Their Immunogenecity in a Mouse Model of Leishmaniasis.
    Hojatizade M; Soleymani M; Tafaghodi M; Badiee A; Chavoshian O; Jaafari MR
    Iran J Immunol; 2018 Dec; 15(4):281-293. PubMed ID: 30593742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcutaneous immunization using SLA or rLACK skews the immune response towards a Th1 profile but fails to protect BALB/c mice against a Leishmania major challenge.
    Lakhal-Naouar I; Koles N; Rao M; Morrison EB; Childs JM; Alving CR; Aronson NE
    Vaccine; 2019 Jan; 37(3):516-523. PubMed ID: 30528328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccination with liposomal leishmanial antigens adjuvanted with monophosphoryl lipid-trehalose dicorynomycolate (MPL-TDM) confers long-term protection against visceral leishmaniasis through a human administrable route.
    Ravindran R; Maji M; Ali N
    Mol Pharm; 2012 Jan; 9(1):59-70. PubMed ID: 22133194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunoliposomes containing Soluble Leishmania Antigens (SLA) as a novel antigen delivery system in murine model of leishmaniasis.
    Eskandari F; Talesh GA; Parooie M; Jaafari MR; Khamesipour A; Saberi Z; Abbasi A; Badiee A
    Exp Parasitol; 2014 Nov; 146():78-86. PubMed ID: 25246326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.